Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu) Pediatric early T-cell precursor leukemia with NF1 deletion and high-sensitivity in vitro to tipifarnib Leukemia (2010) Early T-cell precursor-acute lymphoblastic leukemia (ETP-ALL) is a newly identified high-risk pediatric subtype of ALL, originating from ETPs 1 that retain multilineage differentiation potential. 2 ETP-ALL is characterized by a worse response to standard intensive chemotherapy; therefore, new treatment strategies are needed to improve their outcome. 1 NF1 gene, located at 17q11.2, is a negative regulator of RAS signaling pathway mutated in neurofibromatosis type 1 (Nf1), whose inactivation has been recently identified as a new proliferative hit in pediatric T-cell lymphoblastic leukemia (T-ALL). 3 Tipifarnib is a farnesyl-transferase inhibitor that has demonstrated in vitro and in vivo activity against many hematologic disorders as acute myeloid leukemia. 4, 5 Tipifarnib acts on important signaling molecules including RAS, and promising results were obtained on in vitro sensitivity of pediatric T-ALL blast cells to tipifarnib. 6 We studied a case of a 6-year-old girl affected by T-ALL (expressing cytoplasmic CD3 (97%) and CD7 (96%) antigens), with immunophenotype at diagnosis reflecting the peculiar profile of ETP-ALL 1 (Supplementary Table 1) ; neither cytogenetic abnormalities nor hyperleukocytosis (40 000 white blood cells/mm 3 ) were present at diagnosis. Gene expression profiling performed by principal component analysis of expression of the top 150 differentially expressed probe sets ETP-ALL patients 1 confirmed the clustering with a virtual ETP sample (Figure 1a) . Furthermore, clinical features reflected the typical course of this high-risk subtype of ALL:
1 the patient received chemotherapy according to the AIEOP ALL-2000 Protocol, after a 7 days Prednisone prophase she was classified as poor prednisone responder (Blast Cell Count on peripheral blood 41000 white blood cells/mm 3 ) and failed to achieve complete remission after 33 days of induction treatment. She underwent an allogeneic hematopoietic stem cell transplantation with a human leukocyte antigen-matched unrelated donor, relapsed 1 year after achieving complete remission, and subsequently died of disease. We performed high-resolution genomic screening of bone marrow samples from this patient and nine other pediatric T-ALL patients using 250K single-nucleotide polymorphism array. Parents of all the patients involved in the study signed a specific informed consent in accordance with the Declaration of Helsinki, approved by the Ethical Review Board of Policlinico S. Orsola-Malpighi, stating their consent for scientific use of results.
Heterozygous deletion of NF1 gene was found in leukemic cells of the ETP-ALL patient only (Figure 1b) . Deletion was further confirmed by fluorescence in situ hybridization analysis performed on interphase cells using a dual-color fluorescence in situ hybridization assay for chromosome 17 (Figure 1c) . To investigate the mechanism of potential NF1 inactivation, NF1 expression was measured in blast cells, resulting significantly lower in the ETP-ALL patient, as compared with other nine patients' samples that are wild type for NF1 (Figure 2a) . As NF1 acts as a tumor suppressor gene by negatively regulating RAS pathway, we tested RAS activity in leukemic cells by cytofluorimetric analysis of pERK, a molecule that acts downstream of RAS. Differently from T-ALL patients, RAS resulted activated in a significant percentage of blasts with NF1 deletion (Figure 2b) . Furthermore, this case did not show an activating mutation of FLT3 gene, suggesting that the activation of RAS could be related to NF1 deletion. Other alterations found included 9p21.3 deletion, that is shared by the vast majority of ALL leukemic cells, 5q22.1-q35.3 and 16p13.3 deletions.
The patient described is the first reported case of pediatric ETP-ALL with heterozygous deletion of NF1 gene lacking clinical evidence of Nf1. The deletion of NF1 has already been described in three pediatric T-ALL patients lacking clinical evidence of Nf1, suggesting that NF1 inactivation may provide an additional proliferative hit in pediatric T-ALL. 3 These results support the hypothesis of a somatic rather than a germline origin of NF1 inactivation, suggesting that the deletion of this tumor suppressor gene could be involved in leukemogenesis of ETPs.
Because NF1 encodes a GTPase activating protein for Ras and NF1-deficient leukemic cells show hyperactive Ras signaling, we tested the in vitro sensitivity of tipifarnib, which acts on important signaling molecules including RAS. Tipifarnib has recently been demonstrated to have potential utility in pediatric T-ALL in a vitro screening model. 6 In agreement with previous data, 6 all the samples analyzed in our study were sensitive to tipifarnib; however, response to the drug was significantly higher in ETP-ALL sample (59.88 ng/ml IC 50 ) than in T-ALL samples with wild-type NF1 (Figure 2c ). The maximumtolerated dose of tipifarnib in children is 200 mg/m 2 per dose, and the median steady state concentration at the maximumtolerated dose is 403 ng/ml. 7 In our paper, the IC 50 in ETP-ALL sample was 59.88 ng/ml, more than six times lower than the steady state plasmatic concentration. These data suggest that tipifarnib efficacy could be tested in ETP-ALL patients using well-tolerated dosages. Sensitivity to tipifarnib was recently associated with RASGRP1/APTX expression ratio in acute myeloid leukemia, 8 but we found no significant correlation between the expression of these predictor signature and drug sensitivity. Therefore, the mechanism of action of farnesyltransferase inhibitors in pediatric T-ALL requires further investigations, as confirmed by early studies that showed no correlation between the presence of Ras mutations and the response to tipifarnib. 6 In fact, even if farnesylation is the dominant class of post-translational modification that activates RAS, there are other types of prenylation not inhibited by farnesyltransferase inhibitors that allow RAS attachment to the cell membrane and its participation in signal transduction. 6 Indeed, we can suppose that tipifarnib activity in ETP-ALL cells is at least in part, even if not completely, explained by NF1 inactivation. More experimental data are needed to clarify the real sensitivity of ETP-ALL cells to tipifarnib. This is the first report showing a case of pediatric ETP-ALL with high sensitivity to tipifarnib that could be related to a specific gene (NF1) deletion. Thus, additional studies are needed to analyze NF1 role in patients with ETP-ALL and tipifarnib sensitivity to improve the outcome of this newly identified high-risk subtype of ALL.
